NCT06702631 Nitrous Oxide Neuroimaging
| NCT ID | NCT06702631 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Keith M Vogt |
| Condition | Anesthesia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-01-13 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the effects of acute pain on long-term memory and conditioned physiologic responses in the presence and absence of low dose nitrous oxide. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will occur over 2 visits and involves no long-term follow up.
Eligibility Criteria
Inclusion Criteria: * have none of the specific exclusion criteria * have a valid email address and valid phone number throughout the study * free from any non-MRI compatible implants Exclusion Criteria: * are pregnant or attempting to conceive * body mass index (BMI) \> 35 * significant memory impairment or hearing loss * sleep apnea * chronic pain or frequently taking pain medication (including tramadol) * any severe or poorly-controlled medical problem (hypertension, diabetes) * neurologic or psychiatric disease, including anxiety, and depression * severe cardiac disease * history of methylenetetrahydrofolate reductase (MTHFR) deficiency or variant mutation, as assessed by personal report * recent ear or eye surgery * being claustrophobic * have metal implants or non-removable metal piercings * having a history of adverse reaction to anesthetics * daily alcohol or heavy alcohol use; history of alcohol abuse * current daily smoker * regular or recent marijuana use (including prescribed/medical marijuana) * illicit drug use, i.e., street drugs * regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06702631 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 59 Years, studying Anesthesia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06702631 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06702631 currently recruiting?
Yes, NCT06702631 is actively recruiting participants. Contact the research team at kev18@pitt.edu for enrollment information.
Where is the NCT06702631 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT06702631 clinical trial?
NCT06702631 is sponsored by Keith M Vogt. The trial plans to enroll 60 participants.